Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market
This article was originally published in PharmAsia News
Executive Summary
Takeda submitted an NDA for its dipeptidyl peptidase-4 inhibitor alogliptin (SYR-322) for type 2 diabetes Dec. 27, potentially positioning the Japanese pharma to be second to market with a drug in the class
You may also be interested in...
Takeda’s Alogliptin Falls Prey To U.S. FDA Slowdown
Takeda's alogliptin for type 2 diabetes has become the latest drug to face an open-ended user fee date delay, due to "internal resource constraints" at U.S. FDA
Takeda’s Alogliptin Falls Prey To U.S. FDA Slowdown
Takeda's alogliptin for type 2 diabetes has become the latest drug to face an open-ended user fee date delay, due to "internal resource constraints" at U.S. FDA
Takeda Files For DPP-4 Combo Tablet In U.S., Establishes Asia Hub In Singapore
TOKYO - Takeda Pharmaceutical said Sept. 24 its U.S. R&D subsidiary, Takeda Global Research & Development Center, had applied to the U.S. Food and Drug Administration for approval to market an alogliptin/Actos combination tablet for the treatment of type 2 diabetes